Clinical Trial Update: A Pilot Study to Determine if Raltegravir Eradicates HIV From Peripheral Blood Mononuclear Cells [Phase 4]

View source ↗

Summary

A Phase 4 pilot trial evaluating whether raltegravir can eradicate HIV from peripheral blood mononuclear cells has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acquired Immunodeficiency Syndrome
• Human Immunodeficiency Virus Infection

Drugs mentioned

• Raltegravir (Isentress) (raltegravir)

Snippet

Sponsor: Community Research Initiative of New England | Conditions: HIV Infections, Acquired Immune Deficiency Syndrome | Phase 4 | Status: WITHDRAWN